FTC orders Illumina to divest its $7.1 billion acquisition of cancer test developer Grail
The Federal Trade Commission (FTC) has ordered Illumina to divest its $7.1 billion acquisition of cancer test developer Grail, citing concerns that the deal would stifle innovation and competition in the market for multi-cancer early detection tests. The FTC’s decision…